Chinook hooks $106M, soon to test NASDAQ’s watersChinook Therapeutics Inc. raised $106 million in a venture round as it prepares to reverse-merge with Aduro Biotech Inc. (NASDAQ:ADRO). New investors in the kidney disease company include...

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...

On Friday, Mirum and Fulcrum each filed to raise up to $86.3 million in NASDAQ IPOs. Mirum Pharmaceuticals Inc. (San Francisco, Calif.) launched in November with a $120 million series A round led by New...

Mirum Pharmaceuticals Inc. (San Francisco, Calif.) launched with a $120 million series A round and a license from Shire plc (LSE:SHP; NASDAQ:SHPG) to a pair of candidates to treat liver diseases. The start-up intends to...

Mirum Pharmaceuticals Inc. (San Francisco, Calif.) launched with a $120 million series A round and a license from Shire plc (LSE:SHP; NASDAQ:SHPG) to a pair of candidates to treat liver diseases. The start-up intends to...

With its acquisition by Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) due to close next half, Shire plc (LSE:SHP; NASDAQ:SHPG) reported 5% growth in 2Q18 revenue over 2Q17, outpacing the Japanese pharma's 0.4% growth over the same...

With its acquisition by Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) due to close next half, Shire plc (LSE:SHP; NASDAQ:SHPG) reported 5% growth in 2Q18 revenue over 2Q17, outpacing the Japanese pharma's 0.4% growth over the same...

At least six companies have priced follow-ons since Wednesday’s market close, raising more than $600 million. Gene therapy company Audentes Therapeutics Inc. (NASDAQ:BOLD) raised $201.3 million after hours on Wednesday through the sale of 5.8...